This desk already covers using these drugs when an operation has underdelivered, in after surgery falls short. This study asks a different and commercially live question: whether to run the drug alongside a successful operation from the start, before anything has gone wrong [1].
Patients having sleeve gastrectomy for class II or III obesity were split into those who received semaglutide from months one through six after the operation and those who did not. At twelve months, total body weight loss was 35.14% against 30.73% (P = 0.002), and excess weight loss 86.42% against 76.87% (P = 0.026). The gap was already visible at six months.
The timing is the genuinely interesting part. The drug ran for five months and the primary outcome was measured six months after the last dose, so the difference persisted well beyond treatment. That is unusual for this drug class, where weight generally returns after stopping. A plausible explanation is that the early postoperative months set a trajectory — but it is also exactly the pattern that selection would produce if the patients chosen for the drug were the ones already doing better.
The cost question this raises is not small. Five months of semaglutide on top of an operation, to gain roughly four percentage points of weight loss at a year, is a specific trade a patient can price. Whether that is worth it depends on figures this study does not contain — durability past twelve months, and what the same money does elsewhere — and the break-even arithmetic for drug against surgery is set out in how long the drug takes to cost more and the drug costs you more and the system the same.
One hundred and three patients at a single center is a small basis for a recommendation, and the authors present it as an association rather than a protocol. What it establishes is that the question is worth a randomized trial, which given how many people have both a scheduled operation and access to these drugs is a reasonable thing to ask for. The pre-surgery version of the same timing question is in before bariatric surgery.